Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447193 | 0.89 | LTA4H (0.54) | LTA4HPTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL444836 | 0.88 | LTA4H (0.53) | LTA4HPTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL427937 | 0.83 | KDM4E (0.62) | CYP1A2CYP2D6CYP2C19HSD17B10KDM4E | |
| SCHEMBL448001 | 0.83 | CYP1A2 (0.64) | LTA4HPTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL4270618 | 0.81 | CYP1A2 (0.51) | LTA4HPTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL30950884 | 0.81 | CYP1A2 (0.51) | LTA4HPTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL13946680 | 0.80 | LTA4H (0.55) | LTA4HPTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL4363192 | 0.80 | LTA4H (0.54) | LTA4HPTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL445318 | 0.79 | LTA4H (0.53) | LTA4HPTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL14320670 | 0.76 | SMN1; SMN2 (0.66) | LTA4HPTGS2PTGS1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | LTA4H 324/4885PTGS2 73/4885PTGS1 38/4885 |
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | LTA4H 342/4885PTGS2 118/4885PTGS1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.